WATCH: ‘Strain choice, dose & role are the main probiotic R&D issues'

This content item was originally published on, a William Reed online publication.

By Will Chu

- Last updated on GMT

The translation of microbiome science into commercially viable applications remains an ongoing challenge that needs addressing before consumers are able to reap the mental and physical health benefits.
Ted Dinan
Ted Dinan, professor of psychiatry at University College Cork. ©Ted Dinan

According to University College Cork’s professor of psychiatry Ted Dinan, development of a polybiotic is made all the more difficult by the uncertainty of their specific roles and subsequent chances of survival.

“The challenge initially is to make sure that these strains are not antagonising each other,”​ he explains. “They need to be co-operative if possible but certainly that they can survive together.”

“You don’t want to have a polybiotic with five strains of bacteria, of which three are knocking each other out. So by the time the polybiotic reaches the intestine there are only two strains left.”

Psychobiotic research and development

Professor Dinan, previously chair of clinical neurosciences at St. Bartholomew’s Hospital, London, has a research interest in psychobiotics. He also highlights dose considerations that despite the breadth of microbiome studies remains a matter of debate.

Douwina Bosscher
Douwina Bosscher, global R&D and nutrition sciences leader at Cargill. ©DouwinaBosscher

“We don’t know what the appropriate dosage of these psychobiotics should be​,” he said. “We tend to use 108​ - 109 ​Colony Forming Units (CFU) but there aren’t any adequate dosing studies.”

Dinan was speaking at the MyNewGut Conference in Brussels, where a host of delegates, both from industry and academia gathered to hear the results of the five-year EU funded project and the gut microbiome’s links to obesity, behavioural and lifestyle-related disorders.

A potential application of the microbiome that has stimulated interest from food makers and nutritional researchers is being able to translate causative research into evidence-based nutritional interventions that impact human health positively.

“Where we need to move forward is the need to move form associations to demonstrating causality focusing on the mechanistics ​said Douwina Bosscher, global R&D and nutrition sciences leader at Cargill.

“We can then understand what the effect is of a particular ingredient on the composition of the microbiomeand we can then determine how this impacts the health of the human being.”


Related news

Show more

Related products

show more

Expand into new probiotic possibilities

Expand into new probiotic possibilities

Probi AB | 09-Nov-2021 | Application Note

Expand your product range with innovative probiotic solutions in new health areas. Probi ClinBac™, an exclusive range of patented probiotic health concepts,...



BIONAP Srl | 28-Oct-2021 | Data Sheet

OPUNXIA™ has a high concentrated and standardized polysaccharides profile. It is produced in powder form through specialized technologies to ensure the...

Related suppliers

Follow us


View more